Agilent Technologies Stock News

Agilent Technologies Inc. (NYSE: A) Q4 2021 earnings call dated Nov. 22, 2021 Presentation: Operator Good afternoon and welcome to the Agilent Technologies Fourth Quarter Earnings Conference Call. My name [] The post Agilent Technologies Inc. (A) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .

Agilent Technologies, Inc. (A) CEO Mike McMullen on Q4 2021 Results - Earnings Call Transcript

(RTTNews) - Agilent Technologies Inc. (A) Monday reported fourth-quarter net income of $442 million or $1.45 per share, compared to $222 million or $0.71 per share last year. Adjusted net income was $368 million or $1.21 per share, compared with $305 million or $0.98 per share last year. Revenues for the quarter rose 12% to $1.66 billion from $1.

Agilent Technologies (NYSE:A) reported its Q4 earnings results on Monday, November 22, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces fiscal fourth quarter and full year financial results.

Agilent (A) delivered earnings and revenue surprises of 3.42% and 0.40%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?

Global Mutational Analysis Market Synopsis: An entire Mutational Analysis Market report is spread across more than 350 pages, list of tables & figures, profiling more than ten companies. Analysis and estimations attained through the massive information gathered in this Market report

Global Immunoassay Kits Sales Market Report 2021 The Global Immunoassay Kits Market Research Report 2021-2027 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and

McElhenny Sheffield Capital Management LLC acquired a new position in Agilent Technologies, Inc. (NYSE:A) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,610 shares of the medical research companys stock, valued at approximately $726,000. A number of other institutional []

This weekly article series covers dividend changes. A summary table presents relevant data and key statistics of dividend increases.

The Companion Diagnostics for Oncology Market research report focuses on consolidations and acquisitions, extensions, examination of central participants, the foundation date of organization regions served, fabricating base, and income of vital participants. Moreover, the report also studies breakdown by product